Food and Drug Administration

Anesthetic & Life Support Drugs Advisory Committee

September 9, 2003


FDA's Role in the Risk Management of Opiate Analgesics, Dr. Steven Galson, MD, MPH, FDA (HTM) (PPT)

Risk Management and the Controlled Substances Act: The FDA Perspective, Dr. Deborah Leiderman, MD, MA, FDA (HTM) (PPT)

Presentation by Terrance Woodworth, MS (HTM) (PPT)

Opioid Risk: Benefit Issues, Dr. Arthur Lipman, PharmD, University of Utah Health Sciences Center (HTM) (PPT)

Drug Utilization for Immediate and Modified Release Opioids in the U.S., Dr. Gianna Rigoni, PharmD, MS, FDA (HTM) (PPT)

Aberrant Drug-taking Behaviors in Pain Patients, Dr. Steven Passik, PhD, University of Kentucky (HTM) (PPT)

Abuse of Pain Relievers: Results From the 2002 National Survey on Drug Use and Health (NSDUH), Joe Gfroerer, Substance Abuse and Mental Health Services Administration (HTM) (PPT)

Treatment Episode Data Set, Deborah Trunzo, Substance Abuse and Mental Health Services Administration (HTM) (PPT)

Findings From the Drug Abuse Warning Network, Dr. Judy Ball, PhD, MPA, Substance Abuse and Mental Health Services Administration (HTM) (PPT)

OxyContin® Distribution, Dr. Elizabeth Willis, EdD (HTM) (PPT)

Risk Management Programs, FDA Experience and Evolving Guidances on Risk Management Practices, Dr. Anne Trontell, MD, MPH, FDA (HTM) (PPT)

Opioid Risk Management Programs, Dr. Celia Winchell, MD, FDA (HTM) (PPT)

Open Public Hearing

Education in Long-term Use of Controlled Release Opioids, Dr. Barry Cole, MD, MPA, American Academy of Pain Mgmt (HTM) (PPT)

Overview, Dr. Art Van Zee, MD Virginia (HTM) (PPT)

Optimizing the Risk Management Process: Two Suggestions, Dr. Daniel Carr, MD, Tufts-New England Medical Center (HTM) (PPT)